Neratinib after standard therapy for HER2-positive breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests whether taking neratinib for one extra year can reduce the risk of breast cancer returning in women who had a complete response (no cancer found) after initial treatment but still have high-risk features. It is for women with HER2-positive early breast cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman aged 18 or older.
- Your breast cancer must be HER2-positive and considered early-stage but with high-risk features (like a large tumor or spread to lymph nodes).
- You must have completed neoadjuvant chemotherapy and had a complete response (no cancer seen after surgery).
- You must have completed one year of standard adjuvant therapy, including trastuzumab (Herceptin), and it must have ended no more than 6 months ago.
- You must not have any sign of cancer recurrence or spread.
- You must have a heart function test (LVEF) of at least 50% and be in good overall health (ECOG 0-1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies whether adding neratinib to standard trastuzumab treatment after neoadjuvant (before-surgery) therapy lowers the risk of breast cancer coming back. It is for people whose breast cancer is hormone-receptor positive and HER2 positive, with residual cancer found after neoadjuvant treatment.
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
This trial studies whether adding neratinib to Kadcyla (T-DM1) can help eliminate “molecular residual disease,” meaning tiny traces of cancer left after surgery and standard HER2 treatment. It’s for adults with HER2-positive breast cancer who still test positive after a short course of Kadcyla, with no signs of cancer returning or spreading on scans.
This study tests whether a pre-surgery treatment plan that adds neratinib to hormone therapy and trastuzumab can shrink HER2-positive, ER-positive breast cancer before surgery. It may help patients by improving how much cancer is eliminated at the time of surgery.
This trial tests a treatment for early-stage HER2-positive breast cancer that is small and has not spread to lymph nodes. It aims to reduce the chance of cancer returning after surgery.
This trial tests a combination of two targeted medicines (pyrotinib and trastuzumab) with chemotherapy to treat HER2-positive advanced breast cancer that has returned or spread after stopping trastuzumab.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.